Latest Safety News

Develop Global Limited has marked a pivotal quarter with initial concentrate shipments from its Woodlawn Copper-Zinc Mine, the commencement of earthworks at Sulphur Springs, and a substantial A$180 million capital raise to fuel an aggressive growth strategy.

Radiopharm Theranostics has received FDA clearance to begin a Phase I clinical trial for RV-01, a novel radiopharmaceutical targeting the 4Ig isoform of B7-H3 in solid tumors, marking a significant step forward in cancer treatment innovation.

Carawine Resources advances exploration planning at Paterson and other projects while facing a pivotal court decision on shareholder compulsory acquisition and securing a $1.7 million loan to sustain operations.

Perseus Mining delivered a strong June 2025 quarter, hitting production targets and maintaining a robust cash position of US$827 million, while progressing major projects including the Nyanzaga Gold Project in Tanzania.

Korvest has reported record full-year earnings for FY25, driven by a surge in major project revenue and strong cash flow, while approving a significant expansion of its Kilburn manufacturing facility.

Korvest Ltd reported a strong FY25 with revenues up 16.2% and net profit after tax rising 19.1%, supported by major infrastructure projects and operational resilience. The company declared a fully franked final dividend plus a special dividend, while advancing plans to expand its Kilburn manufacturing site.

Kinetiko Energy has spudded its third gas production test well at Brakfontein and signed a non-binding term sheet with FFS Refiners to co-develop a pilot LNG plant, backed by a recent $2.2 million capital raise.

Supply Network Limited reported solid FY2025 results with 15% revenue growth and expanded its branch footprint, setting sights on further growth despite upcoming operational changes.

Cycliq Group Ltd reported a 7% increase in customer receipts to $4.8 million for FY2025, alongside a positive net operating cash inflow, driven by strong Q4 sales and new digital initiatives.

Kingston Resources has completed the $95 million sale of its Misima Gold Project, bolstering its balance sheet and enabling accelerated growth at its Mineral Hill mine in NSW. The company reports strong operational progress and promising high-grade drilling results.

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.